Technology Based on Pancreatic Enzyme Therapy

Our long-term therapy is based on a pancreatic proenzyme formulation that suppresses tumor recurrence and metastasis.

How Our Technology Works

Halting Cancer Cells’ Ability to Invade and Metastasize

PRP, our lead candidate, controls cancer cell migration, inhibits tumor blood vessel formation and triggers the cell’s death.

How PRP Works

Latest Development

Propanc Discovers PRP Dramatically Suppresses Cancer Stem Cells

Significant Market Opportunity for Cancer Therapy

80% of all cancers are solid tumors. We are initially targeting colorectal and pancreatic tumors.

View the market need for solid tumors

Stock Information | View Detailed Stock Info

OTCQB: PPCHD Propanc Biopharma, Inc.
Day Range
52 Week Range

Get Email Alerts

Stay informed about our latest news and updates